Vertical: CNMBase Year: 2025
Market Size (2025)
$114.92M
Projected (2032)
$161.41M
CAGR (2022–2032)
5.0%
Key Players
8+
Market Overview
The Global Lasalocid Market was valued at USD 114.92 Million in 2025 and is projected to reach USD 161.41 Million by 2032, registering a CAGR of 4.97% during 2026–2032. Over the historic period the market expanded from USD 99.32 Million in 2022 to USD 109.46 Million in 2024, and it is expected to add USD 46.50 Million in absolute value between 2025 and 2032.
Lasalocid is a carboxylic polyether ionophore produced by fermentation of Streptomyces lasaliensis. It is used in animal feed to prevent coccidiosis in poultry and to improve feed efficiency, rate of weight gain and coccidiosis control in cattle, with additional approvals in sheep and certain minor species in several markets. Unlike the monovalent ionophores monensin, salinomycin and narasin, lasalocid transports both monovalent and divalent cations, which gives it a distinct position in anticoccidial rotation and shuttle programmes. Demand is therefore tied to the size of commercial broiler, turkey and cattle populations, to compound feed and premix output, and to the regulatory treatment of in-feed anticoccidials in each country.
The market has a concentrated supply structure. The originator brands, Avatec for poultry and Bovatec for cattle, moved from Zoetis to Phibro Animal Health Corporation with the completion of Phibro's acquisition of the Zoetis medicated feed additive portfolio on 31 October 2024. Downstream, feed manufacturers and mineral supplement producers incorporate lasalocid into complete feeds, supplements, free-choice minerals and blocks.
Key Findings
By Livestock: Cattle and Poultry each accounted for 50.00% of the market in 2025 (USD 57.46 Million each). Cattle is the fastest-growing segment at a CAGR of 5.35%, reaching USD 82.80 Million by 2032, compared with USD 78.61 Million for Poultry (CAGR 4.59%).
By Physical Form: Premix is both the largest and the fastest-growing segment, with a 85.00% share in 2025 (USD 97.68 Million) and a CAGR of 5.18%. The Others segment is projected to grow at a CAGR of 3.76%.
By Region: Asia Pacific is the leading region with a 42.00% share in 2025 (USD 48.27 Million). Middle East & Africa is the fastest-growing region at a CAGR of 5.89%, followed by Asia Pacific (5.54%) and Latin America (5.21%).
By Country: China is the leading country market, valued at USD 19.31 Million in 2025 (16.80% of the global market). India is the fastest-growing country at a CAGR of 7.51%, followed by the UAE (7.14%) and Saudi Arabia (6.67%).
North America and Latin America each held 18.00% of the market in 2025 (USD 20.69 Million each); Latin America grows faster (5.21% versus 4.05%) and is projected to reach USD 29.54 Million by 2032, ahead of North America at USD 27.28 Million.
Segmentation Summary
The market is segmented by livestock (Cattle and Poultry), by physical form (Premix and Others) and by region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa), with country-level estimates for 20 countries and sub-regional groups. Livestock demand is evenly split at the global level in 2025, but the balance differs sharply by region: cattle dominates in North America and Latin America, where lasalocid is widely used for pasture and feedlot cattle, while poultry dominates in Europe, where lasalocid is authorised as a coccidiostat feed additive for poultry. Premix is the dominant physical form because lasalocid is predominantly supplied as a medicated premix or Type A medicated article for incorporation into compound feed at the feed mill.
Competitive Landscape Summary
The lasalocid market is consolidated at the active ingredient and branded premix level and fragmented at the feed manufacturing level. Phibro Animal Health Corporation is the leading supplier following its acquisition of the Zoetis medicated feed additive portfolio, which brought the Avatec and Bovatec lasalocid brands, more than 37 product lines and six manufacturing sites into its portfolio. Huvepharma and Elanco compete in the broader anticoccidial and ionophore space and supply molecules that are approved in the United States for combination use with lasalocid. Feed and mineral manufacturers, including ADM Animal Nutrition, Purina Animal Nutrition, Alltech (Ridley) and the ADM–Alltech joint venture Akralos, are approved to manufacture lasalocid-containing free-choice minerals, blocks and supplements and form the main route to cattle producers.
Challenges and Opportunities
The principal challenges are the shift in parts of the poultry sector toward production programmes that exclude ionophores, rising use of live coccidiosis vaccines and competing anticoccidials, the high toxicity of lasalocid to horses and dogs, which requires strict handling and labelling controls, and dependence on a small number of fermentation-based manufacturing sites. Opportunities arise from expanding broiler and cattle production in Asia Pacific, Latin America and the Middle East & Africa, from the role of lasalocid as a divalent ionophore in anticoccidial rotation programmes that address Eimeria resistance, and from growth in convenient cattle delivery formats such as free-choice minerals, liquid supplements and blocks.
Future Outlook
The market is expected to grow steadily, rising from USD 120.64 Million in 2026 to USD 161.41 Million in 2032. Growth will be led by Asia Pacific, which is projected to add USD 22.19 Million between 2025 and 2032, and by Latin America (USD 8.85 Million). Cattle applications are expected to gain share, rising from 50.00% in 2025 to 51.30% in 2032, supported by pasture and feedlot efficiency programmes. In mature markets such as Europe and North America, growth will be slower and driven by product stewardship, integration of the acquired portfolio by the leading supplier and stable use in established anticoccidial programmes.
The Lasalocid Market market is projected to grow at a CAGR of 5.0% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Lasalocid (lasalocid A, commonly supplied as lasalocid sodium) is a carboxylic polyether ionophore antibiotic obtained by fermentation of Streptomyces lasaliensis. It forms lipid-soluble complexes with monovalent and divalent cations and transports them across cell membranes, disrupting the ionic balance of Eimeria parasites during their early life stages in the gut. In ruminants it modifies rumen fermentation, improving feed efficiency and weight gain. Lasalocid has no use in human medicine and is not classified as a medically important antimicrobial in the United States.
For the purpose of this study, the Global Lasalocid Market includes the value of lasalocid-based products sold for use in animal feed and animal nutrition, covering:
Medicated premixes, Type A medicated articles and feed additive preparations containing lasalocid sodium, in powder or granular form, for incorporation into compound feed;
Other lasalocid formats, including liquid formulations, medicated mineral supplements, free-choice minerals, protein supplements and medicated blocks and tubs;
Use in cattle (beef cattle in confinement and on pasture, replacement heifers and calves) and in poultry (broiler chickens, turkeys and other poultry where authorised).
The study excludes other ionophores and anticoccidials (such as monensin, salinomycin, narasin, maduramicin and semduramicin), chemical anticoccidials, coccidiosis vaccines, laboratory-grade lasalocid sold as analytical or research reagents, and the value of the complete feed into which lasalocid is incorporated.
Scope of the Study
The study covers the following segmentation, as defined in the market estimation data:
By Livestock: Cattle; Poultry
By Physical Form: Premix; Others
By Region: North America (U.S., Canada, Mexico); Europe (Germany, U.K., France, Italy, Spain, Rest of Europe); Asia Pacific (China, India, Japan, Rest of Asia Pacific); Latin America (Brazil, Argentina, Rest of Latin America); Middle East & Africa (UAE, Saudi Arabia, South Africa, Rest of MEA)
Market values are presented in USD Million for the historic years 2022, 2023 and 2024, the base year 2025 and the forecast years 2026 to 2032. Growth rates are expressed as the compound annual growth rate (CAGR) for 2026–2032.
Research Objectives
To estimate the size of the Global Lasalocid Market in value terms for 2022–2024 and 2025, and to forecast it for 2026–2032.
To analyse demand for lasalocid by livestock type (Cattle and Poultry) and to identify how the use pattern differs between pasture, feedlot and poultry production systems.
To assess the market by physical form (Premix and Others) and the role of feed mills, premix manufacturers and mineral supplement producers in product delivery.
To quantify regional and country-level demand across North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
To examine the drivers, restraints, opportunities, trends and challenges affecting lasalocid use, including regulation of in-feed antimicrobials, Eimeria resistance management and the growth of vaccine-based coccidiosis control.
To review the regulatory framework governing lasalocid approval, authorisation, residue limits and feed manufacturing in the major regions.
To analyse the competitive landscape, including the effect of the 2024 transfer of the originator lasalocid brands from Zoetis to Phibro Animal Health Corporation.
To identify the leading companies and their key developments from 2022 onward.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study followed a structured research process combining secondary research, primary research and analytical modelling. The process began with defining the market scope and segmentation, followed by collection of product, regulatory, production and company information from secondary sources. Preliminary estimates were then built through top-down and bottom-up models, validated and refined through primary discussions with industry participants, and finalised through data triangulation. The forecast was prepared using a factor-based approach that links lasalocid demand to livestock production, feed output, regulatory conditions and competitive dynamics.
Secondary Research
Secondary research was used to establish the market definition, identify product approvals and authorisation holders, and collect data on livestock populations, feed production and company performance. The main source types were:
Industry associations: animal health and feed industry bodies such as the International Feed Industry Federation, FEFAC, the American Feed Industry Association, the Animal Health Institute and national poultry and cattle producer associations.
Government and regulatory bodies: the U.S. Food and Drug Administration (Center for Veterinary Medicine), USDA, the European Commission and EFSA, the Canadian Food Inspection Agency, China's Ministry of Agriculture and Rural Affairs, Brazil's Ministry of Agriculture and Livestock, and Australia's APVMA.
Company filings: annual reports, Form 10-K filings, investor presentations and press releases of animal health and feed companies.
Trade journals: animal health, poultry and feed industry publications covering product launches, mergers, acquisitions and regulatory updates.
Paid databases: company financial databases, trade statistics and livestock and feed production datasets.
Primary Research
Primary research was conducted to validate secondary findings, refine market estimates and obtain qualitative insight on usage patterns, pricing and competitive positioning. Interviews were conducted with participants across the value chain.
Supply side: product managers and commercial executives at animal health companies, premix manufacturers, feed additive distributors and medicated feed manufacturers.
Demand side: poultry integrators, feedlot operators, cattle nutritionists, veterinarians, feed mill managers and procurement managers at compound feed companies.
The objectives of primary research were to confirm product usage by species and region, understand the role of lasalocid in anticoccidial programmes and cattle nutrition, validate pricing and dosage assumptions, assess the impact of regulatory changes and the 2024 change in brand ownership, and test the forecast assumptions.
Market Size Estimation
Top-down approach: The global animal health and anticoccidial feed additive markets were used as the starting point. The share of ionophores and, within ionophores, the share of lasalocid was estimated for each region and livestock type using company disclosures, regulatory approvals and expert input. The resulting value was then allocated to countries and physical forms.
Bottom-up approach: Country-level estimates were built from the number of broilers, turkeys and cattle, the proportion of animals receiving lasalocid, typical inclusion rates and duration of use, and average realised prices for premix and other formats. Country estimates were aggregated to regional and global totals.
Data triangulation: The top-down and bottom-up estimates were compared and reconciled. Differences were investigated through additional secondary research and primary interviews, and the final estimates were aligned so that segment, country and regional values are internally consistent.
Forecasting Methodology
The forecast was developed by projecting the base year estimate using growth factors specific to each region, livestock type and physical form. The factors considered include:
Growth in poultry meat production and in cattle herds, feedlot placements and pasture cattle numbers;
Compound feed and premix production trends;
Regulatory developments affecting ionophores and in-feed anticoccidials, including authorisation renewals and restrictions on antimicrobial use;
Adoption of alternative coccidiosis control methods such as vaccines and the share of production under ionophore-free programmes;
Pricing trends, supply capacity and competitive developments, including portfolio integration by the leading supplier;
Macroeconomic conditions, feed grain prices and livestock producer profitability.
Each factor was assessed for its expected impact over the short, medium and long term, and the resulting growth rates were applied to produce annual values for 2026–2032.
Base Year, Forecast Period and Currency
Assumptions and Limitations
Values are expressed in nominal US dollars; exchange rates are assumed to remain broadly stable over the forecast period.
Existing lasalocid approvals and authorisations in the major markets are assumed to remain in force, with no outright ban of ionophores during the forecast period.
No major disruption in lasalocid supply is assumed following the integration of the acquired medicated feed additive portfolio and related manufacturing consolidation.
Disease outbreaks such as highly pathogenic avian influenza are assumed to cause temporary, not permanent, reductions in poultry flock sizes.
Company-level sales of lasalocid are not separately disclosed by most suppliers; segment estimates therefore rely on modelled usage and expert validation.
Estimates for sub-regional groups (Rest of Europe, Rest of Asia Pacific, Rest of Latin America and Rest of MEA) are aggregated and are subject to wider margins than estimates for individually covered countries.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The Global Lasalocid Market is consolidated at the level of the active ingredient and branded premixes and fragmented at the level of feed manufacturing. The originator lasalocid brands, Avatec for poultry and Bovatec for cattle, were developed by Roche, later owned by Alpharma and then Zoetis, and since 31 October 2024 have been owned by Phibro Animal Health Corporation following its acquisition of the Zoetis medicated feed additive portfolio. In the European Union, Phibro Animal Health S.A. is listed as the holder of the Avatec 150 G authorisation. Because product approvals are specific to the holder and to each country, few companies hold lasalocid registrations, and competition at the molecule level is limited.
Competition is more intense at the level of the anticoccidial and ionophore class. In poultry, lasalocid competes with other ionophores, chemical anticoccidials and vaccines for a place in rotation and shuttle programmes; in cattle, it competes mainly with monensin. Animal health companies such as Huvepharma and Elanco supply competing anticoccidials and ionophores, as well as molecules approved for combination use with lasalocid. Downstream, feed and mineral manufacturers such as ADM Animal Nutrition, Purina Animal Nutrition, Alltech (Ridley USA), Akralos and regional mills hold approvals for, or market, lasalocid-containing minerals, blocks and supplements, and compete on nutrition expertise, distribution reach and price. Key competitive factors include regulatory approvals, reliability of supply, technical service, programme design support and cost per treated animal.
Key Player Positioning
Leader: Phibro Animal Health Corporation is the market leader as owner of the Avatec and Bovatec brands, which the company describes as the only divalent ionophore, with fermentation and formulation capacity, global registrations and a sales network focused on medicated feed additives.
Challengers: Huvepharma and Elanco Animal Health are major suppliers of anticoccidials and ionophores and compete with lasalocid for inclusion in poultry and cattle programmes. Both supply molecules approved in the United States for combination use with lasalocid: Huvepharma for bambermycins and tylosin, and Elanco for tylosin.
Niche and channel players: ADM Animal Nutrition, Purina Animal Nutrition, Alltech (Ridley USA), Akralos and Flint River Mills manufacture and market lasalocid-containing free-choice minerals, blocks, protein supplements and medicated feeds, mainly for pasture and feedlot cattle in North America. ADM Animal Nutrition, Purina Animal Nutrition and Ridley USA are named sponsors of lasalocid free-choice formulations in 21 CFR 558.311.
Competitor Dashboard
The dashboard below rates each profiled company on four parameters relevant to the lasalocid market. Ratings are qualitative assessments based on product approvals, geographic reach, partnerships and the length of each company's involvement in animal health and nutrition.
Threat of New Entrants: Low
Product approval requires efficacy, target animal safety, residue and environmental data for each species and country, which takes several years and significant investment.
Fermentation know-how, strain productivity and GMP-certified manufacturing capacity are significant technical barriers.
Established brands and long-standing relationships with integrators and feed mills make customer acquisition difficult for newcomers.
Bargaining Power of Suppliers: Medium
Fermentation substrates, solvents and carriers are widely available commodities with multiple sources.
Energy and specialised equipment costs are significant, and suppliers of these inputs can influence production costs.
Contract manufacturing and fermentation capacity for ionophores is limited, which gives capacity holders some leverage.
Bargaining Power of Buyers: High
Large poultry integrators and feed manufacturers purchase in volume and evaluate anticoccidials on cost per tonne of treated feed.
Buyers can choose among several ionophores, chemical anticoccidials and vaccines in their programmes.
Consolidation of feed manufacturing, such as the formation of Akralos, increases buyer concentration.
Threat of Substitutes: High
Monensin, salinomycin, narasin, maduramicin and semduramicin compete directly as ionophore anticoccidials, and monensin competes in cattle feed efficiency.
Chemical anticoccidials such as nicarbazin, diclazuril, decoquinate and robenidine, and live coccidiosis vaccines, are alternatives in poultry.
Phytogenic additives and other non-antibiotic solutions are increasingly marketed as supporting gut health.
Intensity of Competitive Rivalry: Medium
Only a few suppliers hold lasalocid product registrations, which limits direct molecule-level rivalry.
Competition is intense at the level of the anticoccidial class, where lasalocid competes with other ionophores and chemical products for a place in rotation programmes.
Rivalry centres on technical service, programme design, product availability and price rather than product differentiation alone.
Threat of New Entrants: Low; Regulatory approvals, fermentation know-how and GMP capacity.
Bargaining Power of Suppliers: Medium; Commodity inputs but limited fermentation capacity.
Bargaining Power of Buyers: High; Large integrators and consolidating feed manufacturers; many alternatives.
Threat of Substitutes: High; Other ionophores, chemical anticoccidials and vaccines.
Intensity of Competitive Rivalry: Medium; Few lasalocid suppliers but intense class-level competition.
Market estimates by geography (2032)
InsightAsia Pacific leads with $70.46M by 2032, while Middle East & Africa is projected to grow fastest at a 6.0% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $18.47M | $22.37M | $27.28M | 4.0% | 17% |
| Europe | $15.69M | $18.48M | $22.11M | 3.5% | 14% |
| Asia Pacific | $40.87M | $53.85M | $70.46M | 5.6% | 44% |
| Latin America | $17.58M | $22.91M | $29.54M | 5.3% | 18% |
| Middle East & Africa | $6.70M | $9.04M | $12.03M | 6.0% | 7% |
| Total | $99.32M | $126.64M | $161.41M | 5.0% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$161.41M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Cattle | $82.80M | 5.4% | 51% |
| Poultry | $78.61M | 4.6% | 49% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Lasalocid Market covering market dynamics, competitive landscape, and strategic outlook.
The Lasalocid Market market is projected to reach $161.41M by 2032, growing at 5.0% CAGR. The Cattle segment holds the largest share.
The Global Lasalocid Market is shaped by the economics of poultry and cattle production, by disease pressure from coccidiosis, and by the regulatory treatment of ionophores in each region. The market is projected to grow from USD 114.92 Million in 2025 to USD 161.41 Million in 2032 at a CAGR of 4.97%. This chapter examines the factors that promote or inhibit this growth. The factor scores presented in the growth factor analysis below are analyst assessments based on secondary research and primary interviews, and indicate the relative strength of each factor's impact on market growth on a scale of 1 to 10 for each period.
Expanding Poultry Production and the Burden of Coccidiosis
Poultry meat is the most widely consumed and fastest-growing source of animal protein globally, supported by its low cost per kilogram, short production cycle and absence of major religious restrictions. Production continues to expand in China, Brazil, India, Southeast Asia, Mexico and the Middle East, where integrated broiler operations are increasing in scale. Coccidiosis, caused by Eimeria species, is one of the most economically significant diseases in commercial poultry because it damages the intestinal lining, reduces weight gain and feed conversion, and predisposes birds to necrotic enteritis. In-feed anticoccidials remain the standard preventive tool in conventional broiler and turkey production in most regions. Lasalocid is authorised for coccidiosis prevention in broilers and turkeys in the United States, Canada and the European Union, among other markets, and is included in China's list of veterinary drugs permitted for use in commercial feed under MARA Announcement No. 246. As flock sizes and stocking densities increase, so does the need for reliable coccidiosis prevention, which sustains demand for lasalocid as part of anticoccidial programmes.
Role in Anticoccidial Rotation and Resistance Management
Repeated use of the same anticoccidial reduces the sensitivity of Eimeria populations over time. Poultry producers and veterinarians therefore rotate products between flocks and use shuttle programmes in which different products are fed in starter and grower diets. Lasalocid is described by its marketer as the only divalent ionophore, as it transports divalent cations such as calcium and magnesium in addition to sodium and potassium. This mode of action differs from that of the monovalent ionophores monensin, salinomycin and narasin, which makes lasalocid a useful option for rotation when field isolates show reduced sensitivity to monovalent ionophores. The growing emphasis on structured resistance management by integrators and nutritionists therefore supports continued inclusion of lasalocid in rotation programmes rather than its displacement.
Feed Efficiency Economics in Cattle Production
In cattle, lasalocid alters rumen fermentation toward propionate production, improving the efficiency with which feed energy is converted into weight gain. In the United States it is approved for improved feed efficiency in confinement-fed cattle, increased weight gain in pasture cattle including stocker, feeder and replacement heifers, and coccidiosis control in cattle and calves. The pasture claims are commercially important because they allow lasalocid to be delivered through free-choice minerals, protein supplements and blocks to grazing cattle that are not fed a daily ration. High cattle prices and rising feed costs increase the value of each additional kilogram of weight gain, which strengthens the economic case for ionophore use. In Latin America, especially Brazil and Argentina, the large pasture-based herd and the expansion of feedlot finishing provide substantial headroom for growth, and this is reflected in the faster growth projected for the cattle segment.
Regulatory Status Distinct from Medically Important Antibiotics
Many countries have restricted the use of medically important antimicrobials in feed. In the United States, Guidance for Industry #213 moved medically important antimicrobials used in feed to Veterinary Feed Directive status and removed growth promotion claims; ionophores, including lasalocid, are not considered medically important and remained available over the counter. In the European Union, antibiotic growth promoters were banned from 2006, but coccidiostats such as lasalocid continue to be authorised as feed additives under Regulation (EC) No 1831/2003. China withdrew growth-promoting drug additives from commercial feed from 2020 under MARA Announcement No. 194, while retaining anticoccidials, and lasalocid sodium premix is listed among drugs permitted in commercial feed. This regulatory position allows lasalocid to fill part of the gap left by the withdrawal of other in-feed antibiotics and supports stable demand in regions where antibiotic restrictions have tightened.
Livestock Expansion in Asia Pacific, Latin America and the Middle East & Africa
Rising incomes, urbanisation and population growth are increasing demand for poultry meat and beef in emerging economies. Asia Pacific is projected to grow at a CAGR of 5.54% and Middle East & Africa at 5.89%, both above the global average. Countries such as India, Saudi Arabia and the UAE are expanding commercial poultry capacity, while Brazil and Argentina continue to expand cattle finishing. Registering lasalocid products and building distribution through local premix and feed manufacturers in these markets offers a growth opportunity for suppliers.
Growth in Free-Choice and Ready-to-Feed Cattle Formats
Free-choice minerals, protein supplements, liquid feeds and blocks allow lasalocid to reach grazing cattle that do not receive a daily mixed ration. In the United States, ADM Animal Nutrition, Purina Animal Nutrition and Ridley USA are named sponsors of lasalocid free-choice mineral, block and protein block formulations in the federal regulations, and feed companies such as Hubbard Feeds market minerals containing Bovatec for pasture cattle. Extending these formats to Latin American, Australian and African pasture systems offers a route to growth for the Others segment and for cattle use in general.
Portfolio Integration and Market Development by the Leading Supplier
The transfer of the originator lasalocid brands to Phibro, a company focused on medicated feed additives with established operations across the Americas, Europe, the Middle East and Asia, creates an opportunity for renewed commercial focus on lasalocid. Phibro reported that the acquired portfolio contributed USD 208.2 Million to its net sales in fiscal 2025 and that its "MFAs and other" category reached USD 810.7 Million in fiscal 2026. Integration of sales channels, technical services and registrations across geographies can widen lasalocid availability in markets where it was previously under-represented.
Growth of Ionophore-Free and Antibiotic-Free Production Programmes
In the United States, ionophores are classified as antibiotics for labelling purposes, so poultry raised under "No Antibiotics Ever" programmes cannot receive lasalocid or other ionophores. Several large U.S. integrators adopted such programmes for part of their production during the past decade, replacing ionophores with coccidiosis vaccines and chemical anticoccidials. Similar claims-based programmes exist in some European retail supply chains. Although some producers have since moved back toward "No Human Antibiotics" programmes that permit ionophores, the share of production under ionophore-free programmes limits the addressable poultry market in mature regions and contributes to the slower growth projected for poultry demand in North America and Europe.
Toxicity to Non-Target Species and Handling Requirements
Lasalocid is highly toxic to horses and other equines and is also dangerous to dogs. Product labels in the United States, Canada and Australia carry warnings that equines must not have access to feeds containing lasalocid. Cross-contamination of non-target feed at feed mills is a recognised risk, and the European Union regulates unavoidable carry-over of coccidiostats into non-target feed through Directive 2009/8/EC and sets maximum levels in food through Commission Regulation (EC) No 124/2009. These controls require dedicated handling, flushing and sequencing procedures at mills and limit the use of lasalocid in mixed-species operations, raising compliance costs for feed manufacturers.
Concentrated Supply Base
Production of lasalocid requires fermentation, purification and formulation capacity together with product registrations in each country. The originator brands are held by a single company, and the number of fermentation sites producing lasalocid is limited. Integration of the medicated feed additive portfolio acquired by Phibro in October 2024 includes consolidation of the manufacturing network, such as the planned closure of the Chicago Heights facility announced in August 2026. While consolidation can improve efficiency, a concentrated supply base exposes the market to supply interruptions and limits price competition.
Integrated Coccidiosis Control Combining Vaccines and In-Feed Products
Producers increasingly combine live coccidiosis vaccines with in-feed anticoccidials in planned programmes, for example by alternating vaccine and ionophore cycles to restore Eimeria sensitivity. This trend positions lasalocid as one component of an integrated programme rather than a standalone solution and increases the importance of technical service and programme design.
Consolidation of the Feed Manufacturing Channel
Feed manufacturing in North America is consolidating. ADM and Alltech combined their North American feed businesses into the joint venture Akralos, effective 1 February 2026, bringing together 44 feed mills, including Hubbard Feeds and Masterfeeds. Larger feed manufacturers have greater purchasing power and more structured product selection processes, which influences how medicated additives such as lasalocid are specified and sourced.
Tighter Residue, Carry-Over and Stewardship Requirements
Regulators continue to refine maximum residue limits, withdrawal periods and carry-over limits for coccidiostats. In the European Union, the authorisation of Avatec 150 G for chickens for fattening was renewed under Commission Implementing Regulation (EU) 2023/1172, which also withdrew an older preparation from the market. Compliance with these rules requires investment in quality systems at feed mills and in regulatory dossiers by suppliers.
Price Pressure and Raw Material Costs
Fermentation-based production is exposed to the cost of energy, carbohydrate substrates and solvents, while buyers in the poultry sector operate on narrow margins and evaluate anticoccidials on cost per tonne of feed. Balancing input cost inflation with price-sensitive demand remains a challenge for suppliers, particularly in competitive emerging markets.
The lasalocid value chain runs from fermentation inputs to the livestock producer:
Raw materials and inputs: Fermentation substrates (carbohydrates such as glucose and starch, vegetable oils and protein sources), mineral salts, solvents for extraction and purification, and carriers such as calcium carbonate, rice hulls, corn cob or soybean meal used to formulate premixes. Energy and water are significant cost inputs.
Manufacturing: Production of lasalocid by submerged fermentation of Streptomyces lasaliensis, followed by extraction, purification and conversion to lasalocid sodium. The active ingredient is formulated into medicated premixes, granulates or Type A medicated articles at specialised facilities that hold the required good manufacturing practice certifications and product registrations.
Distribution and channels: Branded premixes are supplied directly or through distributors to compound feed mills, premix and mineral manufacturers, integrators with in-house feed mills and liquid feed and block manufacturers. Feed and mineral manufacturers then incorporate lasalocid into complete feeds, supplements, free-choice minerals, liquids and blocks.
End users: Poultry integrators and growers (broilers, turkeys and other authorised poultry), feedlot operators, cow-calf and stocker operations, dairy heifer rearers and sheep producers. Veterinarians and nutritionists influence product selection and anticoccidial programme design.
North America
United States: Lasalocid is approved by the FDA Center for Veterinary Medicine as a new animal drug for use in animal feed. Conditions of use for chickens, turkeys, cattle, sheep and minor species, including approved combinations, are codified in 21 CFR 558.311, and tolerances for residues are set in 21 CFR 556.347. As an ionophore, lasalocid is not considered medically important and is available without a Veterinary Feed Directive.
Canada: Lasalocid sodium is listed in the Canadian Food Inspection Agency's Compendium of Medicating Ingredient Brochures, which sets approved claims, levels and warnings for medicated feeds under the Feeds Act and its regulations. Veterinary drug approval is handled by Health Canada's Veterinary Drugs Directorate.
Mexico: Veterinary products and medicated feed additives require registration with SENASICA under the Federal Animal Health Law.
Europe
European Union: Lasalocid is authorised as a coccidiostat feed additive under Regulation (EC) No 1831/2003. Commission Implementing Regulation (EU) 2023/1172 authorised Avatec 150 G (lasalocid A sodium) for chickens for fattening, withdrew the older Avatec 15% cc preparation and repealed Regulation (EC) No 1455/2004; the consolidated text lists Phibro Animal Health S.A. as the authorisation holder.
Carry-over of coccidiostats into non-target feed is controlled by Directive 2009/8/EC, and maximum levels in food resulting from unavoidable carry-over are set by Commission Regulation (EC) No 124/2009. Medicated feed is regulated by Regulation (EU) 2019/4.
United Kingdom: Following its exit from the EU, feed additive authorisations in Great Britain are managed by the Food Standards Agency and Food Standards Scotland under retained feed additive legislation.
Asia Pacific
China: The Ministry of Agriculture and Rural Affairs (MARA) regulates veterinary drugs. Announcement No. 194 (2019) withdrew growth-promoting drug feed additives from 2020, and Announcement No. 246 (2020) lists the veterinary drugs permitted in commercial feed, including lasalocid sodium premix.
India: Veterinary drugs are regulated under the Drugs and Cosmetics Act, 1940, administered by the Central Drugs Standard Control Organisation, while residue limits in food are set by the Food Safety and Standards Authority of India.
Japan: Feed additives are designated under the Act on Safety Assurance and Quality Improvement of Feed, administered by the Ministry of Agriculture, Forestry and Fisheries.
Australia: Agricultural and veterinary chemical products, including lasalocid premixes, are registered by the Australian Pesticides and Veterinary Medicines Authority under the Agricultural and Veterinary Chemicals Code.
Latin America and Middle East & Africa
Brazil: Veterinary products are registered with the Ministry of Agriculture and Livestock (MAPA) under Decree-Law No. 467/1969 and its implementing regulation, Decree No. 5,053/2004.
Gulf Cooperation Council: Veterinary products and feed additives require registration with national authorities, such as the Ministry of Climate Change and Environment in the UAE and the Saudi Food and Drug Authority in Saudi Arabia.
South Africa: Farm feeds and stock remedies are registered under the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947), administered by the Department of Agriculture.
June 2023: Avatec 150 G authorisation holder (now Phibro Animal Health S.A.); Regulatory approval; Commission Implementing Regulation (EU) 2023/1172 authorised Avatec 150 G (lasalocid A sodium) as a feed additive for chickens for fattening, withdrew the Avatec 15% cc preparation and repealed Regulation (EC) No 1455/2004.
April 2024: Zoetis Inc. and Phibro Animal Health Corporation; Acquisition agreement; Zoetis agreed to sell its medicated feed additive portfolio, certain water-soluble products and related assets to Phibro for USD 350 Million; the portfolio comprised more than 37 product lines sold in about 80 countries and six manufacturing sites in the U.S., Italy and China.
July 2024: Huvepharma, Inc. and ADM; Partnership; Sales and marketing agreement under which three ADM feed additives (Garlium, Nexulin and Xtract) were added to Huvepharma's U.S. ruminant nutrition portfolio.
October 2024: Phibro Animal Health Corporation; Acquisition; Completed the acquisition of the Zoetis medicated feed additive portfolio, including the Avatec and Bovatec lasalocid brands, on 31 October 2024.
August 2025: Phibro Animal Health S.A.; Regulatory; Consolidated text of Regulation (EU) 2023/1172 lists Phibro Animal Health S.A. as the holder of the Avatec 150 G authorisation.
September 2025: ADM and Alltech; Joint venture; Announced a North American animal feed joint venture combining Alltech's Hubbard Feeds and Masterfeeds with 11 ADM U.S. feed mills, for a total of 44 mills; Alltech retains Ridley Block Operations.
February 2026: Akralos (ADM–Alltech joint venture); Joint venture launch; The joint venture began operating as Akralos, effective 1 February 2026, headquartered in Lexington, Kentucky, and majority owned by Alltech.
August 2026: Phibro Animal Health Corporation; Manufacturing consolidation; Reported fiscal 2026 results with "MFAs and other" sales of USD 810.7 Million and announced the planned closure of its Chicago Heights facility as part of consolidating its manufacturing network after the MFA acquisition.
Political
Government policies on food security and livestock self-sufficiency, such as poultry expansion programmes in Saudi Arabia, support demand for in-feed disease prevention.
Trade policy and tariffs affect cross-border trade in active ingredients and premixes, given the limited number of manufacturing sites.
Public policy on antimicrobial resistance shapes the regulatory treatment of all in-feed antimicrobials, including ionophores.
Economic
Feed grain prices and livestock margins influence producers' willingness to pay for feed additives.
Rising incomes in emerging economies increase per capita consumption of poultry and beef.
Energy and substrate costs affect the cost of fermentation-based production.
Social
Consumer interest in "raised without antibiotics" labels reduces ionophore use in some poultry programmes.
Growing attention to animal welfare favours effective disease prevention that reduces clinical coccidiosis.
Urbanisation and changing diets increase demand for affordable animal protein.
Technological
Improvements in fermentation strain productivity and downstream processing reduce production costs.
Advances in feed manufacturing, such as automated micro-dosing systems, improve accuracy of inclusion and reduce carry-over risk.
Development of coccidiosis vaccines and diagnostic tools for monitoring Eimeria sensitivity influences programme design.
Environmental
Regulators assess the environmental fate of ionophore residues excreted in manure as part of product authorisation.
Improved feed efficiency in cattle reduces feed use per kilogram of gain, which is relevant to the environmental footprint of beef production.
Climate conditions affect coccidiosis pressure, with warm and humid conditions favouring oocyst survival.
Legal
Product approvals, maximum residue limits and withdrawal periods are legally binding and differ by country.
Labelling requirements, including warnings on toxicity to horses, create legal liability for feed manufacturers.
Authorisation holder-specific approvals in the EU tie market access to the holder of each authorisation.
Profiles of 29 companies operating in the Lasalocid Market market, including revenue, employee count, and market positioning where available.
Showing 29 of 29 companies
DuPont de Nemours today is a focused, roughly USD 7 bn-revenue multi-industry company. It is no longer the diversified chemical conglomerate of its heritage. After a decade of portfolio surgery, the company consists of two segments: **Healthcare & Water Technologies (about 47% of FY2025 sales):** Tyvek® medical packaging and protective garments, specialty medical device components (Spectrum, Donatelle), and the FilmTec™ / Amberlite™ water purification franchise. **Diversified Industrials (about 53%):** Building envelope products (Tyvek® house wrap, Styrofoam™, Corian®) and engineered industrial technologies (Molykote®, Vespel®, Betaseal™/Betaforce™ adhesives, Cyrel® printing plates). The company earns a premium-specialty margin profile: operating EBITDA margin was 23.8% in FY2025, with guidance of about 24.5% for FY2026. Management targets 3–4% organic growth, 150–200 bps of margin expansion and 8–10% adjusted EPS CAGR through 2028, supported by a lightly levered BBB+/Baa1 balance sheet. The principal overhang is legacy PFAS liability, shared with Chemours, Corteva and Qnity under contractual arrangements. The principal opportunity is a cleaner, higher-growth healthcare/water mix and capital redeployment. --- **Company's own description (FY2025 10-K, Item 1).** DuPont describes itself as a leading provider of advanced solutions that improve everyday life across healthcare, water, construction and industrial markets. It emphasizes helping customers advance their technology pipelines, from clean water to medical packaging that enhances safety and performance. It names its competitive strengths as: - proprietary product and process technologies; - robust application-development pipelines; - well-known brands; - customer intimacy; - global manufacturing and local service capability. **Independent characterization.** DuPont is now best understood as a specialty engineered-materials and components company with four businesses of roughly comparable scale: **Business model and revenue model.** - Revenue is overwhelmingly product sales: materials, components, membranes, resins, garments and plates. Some engineered systems and modules are sold in Water. - There is no material subscription or licensing revenue. Trade secrets may be licensed occasionally (10-K, Intellectual Property). - The contract manufacturing and design services of Spectrum and Donatelle (medical devices) add a design-in / build-to-print services element, but are recognized as product revenue. - Seasonality: North American Building Technologies demand peaks in Q2–Q3. **Value-chain position.** DuPont sits mid-stream as a Tier-1/Tier-2 supplier. It converts purchased raw materials (polyolefins, specialty monomers, resins, silicones, polymers) into engineered materials, membranes and components. These are specified into customers' finished products: medical devices, sterile packaging, water plants, building envelopes, aircraft, vehicles and print packaging. **Customer types.** - Medical device OEMs and sterile packaging converters - Biopharma manufacturers - Industrial end users and EPC/OEM water-system integrators - Municipalities and desalination operators (via integrators) - Builders, contractors and distributors (e.g., Corian® distribution through Hallmark and Parksite) - Automotive and EV OEMs and Tier-1s - Aerospace OEMs - Printing and packaging converters Most products are sold through DuPont's own sales organization, with distributors used for some lines (10-K, Distribution). **End markets.** Healthcare (medical devices, packaging, biopharma, PPE), water (industrial, municipal/desalination, life sciences, microelectronics UPW), construction (residential, non-residential, repair/remodel) and industrial (aerospace, automotive/EV, printing and packaging, general industrial).
3 interactive charts drawn from the Lasalocid Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Lasalocid Market By Physical Form
Global Lasalocid Market By Livestock
Global Lasalocid Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
